Strain Detail Sheet

Phenotype:
Enhanced myocardial calcium handling and contractile parameters without changes in heart rate. For more information please view http://www.radil.missouri.edu/pheno/Display48140.asp.

Mammalian Phenotype Terms:(provided by MGI)      Extend all MPTs
      assigned by genotype

The following phenotype information may relate to one or more alleles on a genetic background differing from this MMRRC strain.

Pln^tm1Egk/Pln^tm1Egk

        involves: 129S2/SvPas

• cardiovascular system phenotype
  • abnormal cardiac muscle relaxation (MGI Ref ID J:106044)
    • isolated cardiac myocytes exhibit higher relaxation rates (-dL/dt) than wild-type
  • abnormal myocardial fiber physiology (MGI Ref ID J:106044)
    • under baseline conditions, left ventricular myocytes exhibit an enhanced calcium transient amplitude and faster calcium transient decays
    • left ventricular myocytes do not show an increase in the intracellular calcium transient amplitudes or accelerated calcium transient decays when treated with isoproterenol as is seen in wild-type
  • increased cardiac muscle contractility (MGI Ref ID J:106044)
    • isolated cardiac myocytes exhibit a significant increase in fractional cell shortening and higher dL/dT values
• muscle phenotype
  • abnormal cardiac muscle relaxation (MGI Ref ID J:106044)
    • isolated cardiac myocytes exhibit higher relaxation rates (-dL/dt) than wild-type
  • increased cardiac muscle contractility (MGI Ref ID J:106044)
    • isolated cardiac myocytes exhibit a significant increase in fractional cell shortening and higher dL/dT values

Pln^tm1Egk/Pln^tm1Egk

        involves: 129S2/SvPas * CF-1 * FVB/N

• cardiovascular system phenotype
  • increased heart weight (MGI Ref ID J:134706)
    • the heart weight to bod y weight ratio is 10% greater compared to controls

Pln^tm1Egk/Pln^tm1Egk

        involves: 129S2/SvPas * CF1

• cardiovascular system phenotype
  • abnormal heart left ventricle pressure (MGI Ref ID J:39745)
    • diastolic and end diastolic pressures were decreased
    • rates of pressure development were increased
    • systolic intraventricular pressure increased
  • increased cardiac muscle contractility (MGI Ref IDs J:39745, J:59967)
    • no increased contractility in response to beta-adrenergic agonists (MGI Ref ID J:39745)
    • large force developed at low frequencies of stimulation but more like controls at higher frequencies (MGI Ref ID J:59967)
    • no acceleration of time to peak tension with increasing frequency of stimulation, similar observation for relaxation time (MGI Ref ID J:59967)
    • declining rate of force development with increased frequency of stimulation (MGI Ref ID J:59967)
• muscle phenotype
  • increased cardiac muscle contractility (MGI Ref IDs J:39745, J:59967)
    • no increased contractility in response to beta-adrenergic agonists (MGI Ref ID J:39745)
    • large force developed at low frequencies of stimulation but more like controls at higher frequencies (MGI Ref ID J:59967)
    • no acceleration of time to peak tension with increasing frequency of stimulation, similar observation for relaxation time (MGI Ref ID J:59967)
    • declining rate of force development with increased frequency of stimulation (MGI Ref ID J:59967)

Founder genetic background: (129X1/SvJ x CF-1) F1

Strain genetic background: 129X1/SvJ/CF-1

Strain Development:
Phospholamban-targeted ES cells were injected into C57BL/6 blastocysts and transferred to F1(C3H HeN x C57BL/6J) pseudopregnant females. Coat-color offspring were mated to albino nonagouti CF-1 mice. Resulting heterozygous mice carrying the targeted phospholamban allele were mated to produce homozygous mutant mice completely deficient in phospholamban.

Donor: Dr. Evangelia Kranias, University of Cincinnati College of Medicine

Primary Reference:

Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res. 1994 Sep;75(3):401-9. (Medline: PMID 8062415)

Coat color: Agouti

Other:

MMRRC Breeding System: Sib mating

Breeding Scheme(s):

• Homozygous Female x Homozygous Male

Generation: Unknown

Overall Breeding Performance: Good

Viability and Fertility	Female	Male
Homozygotes are viable:	Yes	Yes
Homozygotes are fertile:	Yes	Yes
Heterozygotes are fertile:	Yes	Yes
Age Reproductive Decline:	6 - 7 months	6 - 7 months

Older breeding males may become aggressive.

Additional charges may apply for any special requests. Shipping costs are in addition to the basic distribution/resuscitation fees. Information on shipping costs and any additional charges will be provided by the supplying MMRRC facility.

Click button to Request this one strain. (Use the MMRRC Catalog Search to request more than one strain.) Request this Strain
MMRRC Item # Description	Distribution Fee/unit (US $)	Units	Notes
000027-MU-RESUS Litter recovered from cryo-archive	$2,022.00 Non-Profit	Litter	Recovered litter1; additional fees for any special requests.
000027-MU-SPERM Cryo-preserved spermatozoa	$437.00 Non-Profit	Aliquot	Approximate quantity.2

¹ The distribution fee covers the expense of resuscitating mice from the cryo-archive; you will receive the resulting litter. The litter will contain at minimum one breedable mutant carrier; the actual number of animals and the gender and genotype ratios will vary. (Typically, multiple breeder pairs can be established from the recovered litter.) Prior to shipment, the MMRRC will provide information about the animals recovered. If you anticipate or find that you need to request specific genotypes, genders or quantities of mice in excess of what is likely from a resuscitated litter, you may discuss available options and pricing with the supplying MMRRC facility.

² An aliquot contains sufficient material (volume and concentration) for at least two IVF or several artificial inseminations (based on our procedures). The MMRRC makes no guarantee concerning success of these procedures when performed outside the MMRRC facilities.

³ An aliquot contains a sufficient number of embryos (in one or more vials and based on the transfer success rate of the MMRRC facility) to transfer to at least two recipients. The MMRRC makes no guarantee concerning embryo transfer success experienced in the recipient investigator's laboratory. Neither gender nor genotype ratios are guaranteed.